ABSTRACT
Key Points ......................................................................................................................................265 Introduction ....................................................................................................................................266 Fructose-Potential Link Between Sugar Consumption and Metabolic Disease ..........................266 Regulation of Hepatic Glucose Metabolism .................................................................................. 267 Regulation of Hepatic Fructose Uptake ......................................................................................... 267 Fructokinase C ...............................................................................................................................268 De Novo Lipogenesis .....................................................................................................................269 Fatty Acid Oxidation ......................................................................................................................269 Hepatic Lipid and VLDL Production .............................................................................................269 Dyslipidemia .................................................................................................................................. 270 Postprandial Triglyceride and Proatherogenic Conditions ............................................................ 270 Hepatic Lipid and Insulin Sensitivity............................................................................................. 270 Whole-Body Insulin Sensitivity ..................................................................................................... 271 Uric Acid ........................................................................................................................................ 271 Inammatory Factors ..................................................................................................................... 272 Hepatic Insulin Resistance and DNL ............................................................................................. 273 Hepatic Insulin Resistance and VLDL Production ........................................................................ 273 Muscle Lipid Accumulation ........................................................................................................... 273 Summary ........................................................................................................................................ 275 Conclusion ..................................................................................................................................... 275 References ...................................................................................................................................... 275
• Increased hepatic lipid supply is associated with increased production of large very-lowdensity lipoprotein 1 (VLDL1) particles and dyslipidemia.
